mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Cited by (962)

Items 401–500 of 962

1. Hypoxia induces a phase transition within a kinase signaling network in cancer cells
   Wei Wei, Qihui Shi, F. Remacle, Lidong Qin, David B. Shackelford, Young Shik Shin, Paul S. Mischel, Raphael David Levine, James R. Heath · 2013 · Proceedings of the National Academy of Sciences
2. Leucine reduces reactive oxygen species levels via an energy metabolism switch by activation of the mTOR-HIF-1α pathway in porcine intestinal epithelial cells
   Jun Ping Hu, Yangfan Nie, Shifeng Chen, Chunlin Xie, Qiwen Fan, Zhichang Wang, Baisheng Long, Guokai Yan, Qing Zhong, Xianghua Yan · 2017 · The International Journal of Biochemistry & Cell Biology
3. Ti 3 C 2 T x MXene Composite 3D Hydrogel Potentiates mTOR Signaling to Promote the Generation of Functional Hair Cells in Cochlea Organoids
   Zhong Zhang, Shan Gao, Yangnan Hu, Xin Chen, Cheng Cheng, Xiaolong Fu, Sha‐Sha Zhang, Xin‐Lin Wang, Yu‐Wei Che, Chen Zhang et al. · 2022 · Advanced Science
4. A review of therapies for diabetic macular oedema and rationale for combination therapy
   Winfried M. K. Amoaku, Shay Saker, Elizabeth Anne Stewart · 2015 · Eye
5. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway
   Beat C. Bornhauser, Laura Bonapace, Dan Lindholm, Rodrigo M. Maza, Gunnar Cario, Martin Schrappe, Felix K Niggli, Beat W. Schäfer, Jean‐Pierre Bourquin · 2007 · Blood
6. Rapamycin Inhibits Proliferation of Estrogen-Receptor-Positive Breast Cancer Cells
   Sharon B. Chang, Penelope L. Miron, Alexander Miron, James Dirk Iglehart · 2006 · Journal of Surgical Research
7. A Randomized, Dose-Escalation Study of Subconjunctival and Intravitreal Injections of Sirolimus in Patients with Diabetic Macular Edema
   Pravin U. Dugel, Mark Scott Blumenkranz, Julia A. Haller, George A. Williams, WAYNE A. SOLLEY, David M Kleinman, Joel Naor · 2011 · Ophthalmology
8. AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B
   Jia Xu, Xufen Yu, Tiphaine C. Martin, Ankita Bansal, Kakit Cheung, Abigail Lubin, Elias Stratikopoulos, Kaitlyn M. Cahuzac, Li Wang, Ling Xie et al. · 2021 · Cancer Discovery
9. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions
   Julio Pascual, Ioannis N Boletis, Josep Maria Campistol · 2006 · Transplantation Reviews
10. Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation
    Samira Alliouachene, Robyn L. Tuttle, Stéphanie Boumard, Thomas Lapointe, Sophie Bérissi, Stéphane Germain, Francis Jaubert, David Tosh, Morris J. Birnbaum, Mario Pende · 2008 · Journal of Clinical Investigation
11. The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer
    Bodo Clemens Melnik, Swen Malte John, Pedro Carrera‐Bastos, Loren Cordain · 2012 · Nutrition & Metabolism
12. Genetically engineered mouse models of prostate cancer
    Maxime Parisotto, Daniel METZGER · 2013 · Molecular Oncology
13. A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice
    Sang‐Hyun Lee, George Poulogiannis, Saumyadipta Pyne, Shidong Jia, Lihua Zou, Sabina Signoretti, Massimo F. Loda, Lewis C. Cantley, Thomas M. Roberts · 2010 · Proceedings of the National Academy of Sciences
14. mTOR Mediates Survival Signals in Malignant Mesothelioma Grown as Tumor Fragment Spheroids
    Shannon M. Wilson, Dario Barbone, Tsung‐Ming Yang, David M. Jablons, Raphael Bueno, David J. Sugarbaker, Stephen L. Nishimura, Gavin J. Gordon, V. Courtney Broaddus · 2008 · American Journal of Respiratory Cell and Molecular Biology
15. TORgeting oncogene addiction for cancer therapy
    Andrew Y. Choo, John Blenis · 2006 · Cancer Cell
16. CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma
    Mark N. Stein, Keith T. Flaherty · 2007 · Clinical Cancer Research
17. Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta‐analysis
    Kenya Yamanaka, Marius Petrulionis, Shibo Lin, Chao Gao, Uwe Galli, Susanne Richter, Susanne Winkler, Philipp Houben, Daniel P. Schultze, Etsuro Hatano et al. · 2013 · Cancer Medicine
18. Everolimus
    Jens Hasskarl · 2014 · Recent results in cancer research/Recent Results in Cancer Research
19. S6K1 Plays a Key Role in Glial Transformation
    Jean L. Nakamura, Edna Garcia, Russell O. Pieper · 2008 · Cancer Research
20. Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology
    Debora Fumagalli, Alexis Blanchet-Cohen, David N. Brown, Christine Desmedt, David Gacquer, Stefan Michiels, Françoise Rothé, Samira Majjaj, Roberto Salgado, Denis Larsimont et al. · 2014 · BMC Genomics
21. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers
    Debora Fumagalli, Timothy Richard Wilson, Roberto Salgado, Xuyang Lu, Jianjun Yu, Carol Lynn O'Brien, K. Walter, L Huw, Carmen Criscitiello, I. Laïos et al. · 2016 · Annals of Oncology
22. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
    Todd Matthew Morgan, Tiffany E.M. Pitts, Ted S. Gross, Sandra L. Poliachik, Robert L. Vessella, Eva Corey · 2008 · The Prostate
23. Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
    Matteo Santoni, Francesco Pantano, Consuelo Amantini, Massimo Nabissi, Alessandro Conti, Luciano Burattini, Alice Zoccoli, Rossana Berardi, Giorgio Santoni, Giuseppe Tonini et al. · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
24. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance
    Wei‐Yu Chen, Yu‐Ching Wen, Shian‐Ren Lin, Hsiu-Lien Yeh, Kuo-Ching Jiang, Weihao Chen, Yow-Sien Lin, Qingfu Zhang, Phui‐Ly Liew, Michael Hsiao et al. · 2021 · Communications Biology
25. Targeting mTOR for Anti-Aging and Anti-Cancer Therapy
    Wencheng Fu, Geng Wu · 2023 · Molecules
26. Frequent Gene Products and Molecular Pathways Altered in Prostate Cancer- and Metastasis-Initiating Cells and Their Progenies and Novel Promising Multitargeted Therapies
    Murielle Mimeault, Surinder K. Batra · 2011 · Molecular Medicine
27. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
    Mark R. Morris, David J. Hughes, Ya-Min Tian, Christopher J. Ricketts, Kah Weng Lau, Dean Gentle, Salwati Shuib, Pablo Serrano‐Fernández, Jan Lubiński, Michael Sean Wiesener et al. · 2009 · PubMed
28. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis
    Ying‐Ying Lee, Myth T.S. Mok, Wei Kang, Weiqin Yang, Wenshu Tang, Feng Wu, Liangliang Xu, Mingfei Yan, Zhuo Yu, Sau-Dan Lee et al. · 2018 · Nucleic Acids Research
29. miR-142 controls metabolic reprogramming that regulates dendritic cell activation
    Yaping Sun, Katherine I. Oravecz-Wilson, Sydney Bridges, Richard C. McEachin, Julia J. Wu, Stephanie H. Kim, Austin Taylor, Cynthia K. Zajac, Hideaki Fujiwara, Daniel Peltier et al. · 2019 · Journal of Clinical Investigation
30. Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update
    Giuseppe Tiziano Lucarelli, Davide Loizzo, Matteo Ferro, Monica Rutigliano, Mihai Dorin Vartolomei, Francesco Cantiello, Carlo Buonerba, Giuseppe Di Lorenzo, Daniela Terracciano, Ottavio DE COBELLI et al. · 2019 · Expert Review of Molecular Diagnostics
31. Akt pathway as a target for therapeutic intervention in HNSCC.
    M Moral, Jesús María Paramio · 2008 · PubMed
32. Proliferation Signal Inhibitors in Transplantation: Questions at the Cutting Edge of Everolimus Therapy
    Jeremy Robert Chapman, Hannah A. Valantine, Joan Albanell, Wolfgang Arns, Josep Maria Campistol, Howard J. Eisen, Maria Frigerio, Hans Brendan Lehmkuhl, R. Marcén, Randall Ellis Morris et al. · 2007 · Transplantation Proceedings
33. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
    Meysam Moghbeli · 2021 · Journal of Ovarian Research
34. Evaluation of the Role of Hexokinase Type II in Cellular Proliferation and Apoptosis Using Human Hepatocellular Carcinoma Cell Lines
    Keun Jae Ahn, Hee Sung Hwang, Jeon Han Park, Seong-Hye Bang, Won Jun Kang, Mijin Yun, Jong Doo Lee · 2009 · Journal of Nuclear Medicine
35. mTOR signaling in human cancer
    Joan Albanell, Alba Dalmases, Ana Rovira, Federico Rojo · 2007 · Clinical & Translational Oncology
36. Isoflurane Preconditioning Decreases Myocardial Infarction in Rabbits via Up-regulation of Hypoxia Inducible Factor 1 That Is Mediated by Mammalian Target of Rapamycin
    Jacob Raphael, Zhiyi Zuo, Suzan Abedat, Rоnen Beeri, Yaacov Gozal · 2008 · Anesthesiology
37. Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
    Robert John Amato, Jaroslaw Jac, Taqi Mohammad, Somyata Saxena · 2008 · Clinical Genitourinary Cancer
38. Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer
    Francesco M. Lasorsa, Nicola Antonio di Meo, Monica Rutigliano, Matteo Ferro, Daniela Terracciano, Octavian Sabin Tătaru, Michele Battaglia, Pasquale Ditonno, Giuseppe Tiziano Lucarelli · 2023 · International Journal of Molecular Sciences
39. Prostatic preneoplasia and beyond
    Anthony Michael Joshua, A. Evans, Theodorus van der Kwast, Maria Zieleńska, Alan Keith Meeker, Arul M. Chinnaiyan, Jeremy Andrew Squire · 2007 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
40. Mutual Regulation of Hypoxia-Inducible Factor and Mammalian Target of Rapamycin as a Function of Oxygen Availability
    Karl Xaver Knaup, Katrin Jozefowski, Regina Schmidt, Wanja M. Bernhardt, Alexander Weidemann, Jan Steffen Jürgensen, Christina Warnecke, Kai‐Uwe Eckardt, Michael Sean Wiesener · 2009 · Molecular Cancer Research
41. Postprandial regulation of hepatic glucokinase and lipogenesis requires the activation of TORC1 signaling in rainbow trout (Oncorhynchus mykiss)
    Weiwei Dai, Stéphane Panserat, Jan Alexander Mennigen, Frédéric Terrier, Karine Dias, Iban Seiliez, Sandrine Cassy · 2013 · Journal of Experimental Biology
42. The mammalian target of rapamycin signaling network and gene regulation
    Ghada A. Soliman · 2005 · Current Opinion in Lipidology
43. Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer
    Yulun Wu, Chaoran Jia, Wei Liu, Wei Zhan, Yao Chen, Junlin Lu, Yongli Bao, Shuyue Wang, Chunlei Yu, Lihua Zheng et al. · 2024 · Journal of Advanced Research
44. KLF5 promotes hypoxia-induced survival and inhibits apoptosis in non-small cell lung cancer cells via HIF-1α
    Xiaochen Li, Xiansheng Liu, Yongjian Xu, Jin Liu, Min Xie, Ni Wang, Shixin Chen · 2014 · International Journal of Oncology
45. Dual Targeting of mTOR and Aurora-A Kinase for the Treatment of Uterine Leiomyosarcoma
    Kari J. Brewer Savannah, Elizabeth G. Demicco, Kristelle Lusby, Markus PH. Ghadimi, Roman Belousov, Eric D. Young, Yiqun Zhang, Kai-Lieh Huang, Alexander J. Lazar, Kelly K. Hunt et al. · 2012 · Clinical Cancer Research
46. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD
    Yuria Saito, Yuko Tanaka, Yuichi Aita, Kiyo‐aki Ishii, Tatsuhiko Ikeda, Kazumasa Isobe, Yasushi Kawakami, Hitoshi Shimano, Hisato Hara, Kazuhiro Takekoshi · 2011 · American Journal of Physiology-Endocrinology and Metabolism
47. Matrine Reverses the Warburg Effect and Suppresses Colon Cancer Cell Growth via Negatively Regulating HIF-1α
    Xiaoting Hong, Linhai Zhong, Yurou Xie, Kaifeng Zheng, Jinglong Pang, Yesen Li, Yifan Yang, Xiaolin Xu, Panying Mi, Hanwei Cao et al. · 2019 · Frontiers in Pharmacology
48. siRNA screen of the human signaling proteome identifies the PtdIns(3,4,5)P3-mTOR signaling pathway as a primary regulator of transferrin uptake
    Thierry Galvez, Mary N. Teruel, Won Do Heo, Joshua Timothy Jones, Man Lyang Kim, Jen Liou, Jason W. Myers, Tobias Meyer · 2007 · Genome biology
49. The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
    Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, Bastien Nguyen, Konrad Hermann Stopsack, Christoph K. Kreitzer, Sai Harisha Rajanala, Romina Ghale, Ying Zhang Mazzu, Nagavarakishore Pillarsetty et al. · 2022 · Clinical Cancer Research
50. Targeting Aerobic Glycolysis and HIF-1α Expression Enhance Imiquimod-induced Apoptosis in Cancer Cells
    Shi‐Wei Huang, Jun‐Kai Kao, Chun‐Ying Wu, Sin-Ting Wang, Hsin‐Chen Lee, Shu‐Mei Liang, Yi–Ju Chen, Jeng‐Jer Shieh · 2014 · Oncotarget
51. Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis
    Zhimin Lu · 2011 · 癌症：英文版
52. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
    Laura S Graham, Michael Thomas Schweizer · 2016 · Medical Oncology
53. The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention
    Levy Kopelovich, Judith R. Fay, Caroline C. Sigman, James A. Crowell · 2007 · Cancer Epidemiology Biomarkers & Prevention
54. Somatic stem cells and the origin of cancer
    Jose Angel Martinez-Climent, Enrique José Andreu, Felipe Prósper · 2006 · Clinical & Translational Oncology
55. Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy
    Hiroaki Ikeda, Hideaki Kakeya · 2021 · The Journal of Antibiotics
56. Rapamycin Partially Mimics the Anticancer Effects of Calorie Restriction in a Murine Model of Pancreatic Cancer
    Laura M. Lashinger, Lauren M. Malone, Graham William Brown, Elizabeth A. Daniels, Jason A. Goldberg, Glen M. Otto, Susan M. Fischer, Stephen David Hursting · 2011 · Cancer Prevention Research
57. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
    Samuel W. Brady, Jian Zhang, Ming-Horng Tsai, Dihua Yu · 2015 · Cancer Biology & Therapy
58. RETRACTED: Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERα
    Vincenzo Nicola Talesa, Ivana Ferri, Guido Bellezza, Harold D. Love, Angelo Sidoni, Cinzia Antognelli · 2016 · The Prostate · Retracted
59. Noscapine inhibits hypoxia-mediated HIF-1α expression andangiogenesis in vitro: a novel function for an old drug
    Elizabeth W. Newcomb, Yevgeniy Lukyanov, Tona Schnee, M. Ali, Lan Li, David Zagzag · 2006 · International Journal of Oncology
60. Nutrient Sensing in Cancer
    Margaret E. Torrence, Brendan D. Manning · 2017 · Annual Review of Cancer Biology
61. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations
    David James Pinato, Radha Ramachandran, S T K Toussi, Marco Vergine, N Ngo, Rohini Sharma, Tyler Lloyd, Karim M. Meeran, Fausto F Palazzo, N Martin et al. · 2012 · British Journal of Cancer
62. A framework to identify physiological responses in microarray-based gene expression studies: selection and interpretation of biologically relevant genes
    Wendy Rodenburg, A. Geert Heidema, Jolanda M.A. Boer, Ingeborg M. J. Bovee-Oudenhoven, Edith J. M. Feskens, Edwin C.M. Mariman, Jaap Keijer · 2007 · Physiological Genomics
63. uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells
    Anna Laurenzana, Anastasia Chillà, Cristina Luciani, Silvia Peppicelli, Alessio Biagioni, Francesca Bianchini, Elena Tenedini, Eugenio Torre, Alessandra Mocali, Lido Calorini et al. · 2017 · International Journal of Cancer
64. Precancer in Mice: Animal Models Used to Understand, Prevent, and Treat Human Precancers
    Robert D. Cardiff, Miriam R. Anver, Gregory P. Boivin, Marcus Bosenberg, Robert R. Maronpot, Alfredo Molinolo, Alexander Yu. Nikitin, Jerold E. Rehg, GEORGE V. THOMAS, Robert G. Russell et al. · 2006 · Toxicologic Pathology
65. RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism
    Wenke Wang, Bei Shi, Ruiting Cong, Mingjun Hao, Yuanyuan Peng, Hongyue Yang, Jiahui Song, Di Feng, Naijin Zhang, Da Li · 2022 · Cell Death Discovery
66. The Role of External Beam Radiation and Targeted Therapy in Thyroid Cancer
    James D. Brierley, Eric Jeffrey Sherman · 2012 · Seminars in Radiation Oncology
67. Targeted therapies in renal cell cancer: recent developments in imaging
    Astrid A.M. van der Veldt, Martijn Ruben Meijerink, Alfons J.M. van den Eertwegh, Epie Boven · 2010 · Targeted Oncology
68. Metabolic changes in bladder cancer
    Benjamin Leeland Woolbright, Matthew Ayres, John Arthur Taylor · 2018 · Urologic Oncology Seminars and Original Investigations
69. Emerging Role of mTOR Signaling‐Related miRNAs in Cardiovascular Diseases
    Arun Samidurai, Rakesh C. Kukreja, Anindita Das · 2018 · Oxidative Medicine and Cellular Longevity
70. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation
    Sharmila Prabhu, D Saadat, Maggie Zhang, L Halbur, John P. Fruehauf, S. Tiong Ong · 2006 · Oncogene
71. Novel dual-color immunohistochemical methods for detecting ERG–PTEN and ERG–SPINK1 status in prostate carcinoma
    Ritu Bhalla, Lakshmi Priya Kunju, Scott A. Tomlins, Kelly Christopherson, Connie C. Cortez, Shannon L. Carskadon, Javed Siddiqui, Kyung Park, Juan Miguel Mosquera, Gary Anthony Pestano et al. · 2013 · Modern Pathology
72. EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans
    Carlos L. Arteaga · 2006 · Cancer Cell
73. Hypoxia-inducible factor–1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma
    Matthew Robert Womeldorff, David L. Gillespie, Randy L. Jensen · 2014 · Neurosurgical FOCUS
74. Advances in mouse models of prostate cancer
    Imran Ahmad, Owen James Sansom, Hing Y. Leung · 2008 · Expert Reviews in Molecular Medicine
75. The pros and the cons of mTOR inhibitors in kidney transplantation
    Claudio E. Ponticelli · 2013 · Expert Review of Clinical Immunology
76. Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells
    Esraah Sattar Alharris, Narendra Prasad Singh, Prakash S. Nagarkatti, Mitzi Nagarkatti · 2019 · Oncotarget
77. Targeting hypoxia and angiogenesis through HIF-1alpha inhibition
    Juan Antonio Díaz-González, James Russell, Ana Rouzaut, Ignacio Gil Bazo, Luis M. Montuenga · 2005 · Cancer Biology & Therapy
78. The Tuberous Sclerosis Complex Regulates Trafficking of Glucose Transporters and Glucose Uptake
    Xiuyun Jiang, Heidi L. Kenerson, Lauri D. Aicher, Robert S. Miyaoka, Janet F. Eary, John J. Bissler, Raymond S. W. Yeung · 2008 · American Journal Of Pathology
79. Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
    Joan T. Garrett, Anindita Chakrabarty, Carlos L. Arteaga · 2011 · Oncotarget
80. Celastrol Stimulates Hypoxia-Inducible Factor-1 Activity in Tumor Cells by Initiating the ROS/Akt/p70S6K Signaling Pathway and Enhancing Hypoxia-Inducible Factor-1α Protein Synthesis
    Xiaoxi Han, Shengkun Sun, Ming Zhao, Xiang Cheng, Guozhu Chen, Song Lin, Yifu Guan, Xiaodan Yu · 2014 · PLoS ONE
81. NCCN Task Force Report: mTOR Inhibition in Solid Tumors
    Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes et al. · 2008 · Journal of the National Comprehensive Cancer Network
82. Transient mTOR Inhibition Facilitates Continuous Growth of Liver Tumors by Modulating the Maintenance of CD133+ Cell Populations
    Zhaojuan Yang, Li Zhang, Aihui Ma, Lanlan Liu, Jinjun Li, Jianren Gu, Yongzhong Liu · 2011 · PLoS ONE
83. Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells
    Yan Liu, Shi‐Yong Sun, Taofeek Kunle Owonikoko, Gabriel Sica, Walter John Curran, Fadlo Raja Khuri, Xingming Deng · 2011 · Molecular Cancer Therapeutics
84. Hypoxia-inducible factor-1alpha: A promising therapeutic target in endometriosis
    Lei Zhan, Wenyan Wang, Yu Zhang, Enxue Song, Yijun Fan, Bing Wei · 2016 · Biochimie
85. Oxidative stress and metabolic reprogramming in Cr(VI) carcinogenesis
    Marco Clementino, Xianglin Shi, Zhuo Zhang · 2017 · Current Opinion in Toxicology
86. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin‐resected hepatocellular carcinoma
    Hideo Andreas Baba, Jeremias Wohlschlaeger, Vito Rosario Cicinnati, Philip a. Hilgard, Hauke Lang, Georgios Charalambos Sotiropoulos, Atsushi Takeda, Susanne Beckebaum, Klaus J. Schmitz · 2009 · Liver International
87. Multiple Oncogenic Pathway Signatures Show Coordinate Expression Patterns in Human Prostate Tumors
    Chad J. Creighton · 2008 · PLoS ONE
88. mTOR inhibitors in pediatric kidney transplantation
    Lars Pape, Thurid Ahlenstiel · 2013 · Pediatric Nephrology
89. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics
    Bo Dai, Yun Yi Kong, Ding Wei Ye, Chun-guang Ma, Xiaoyan Zhou, Xu Yao · 2009 · British Journal of Urology
90. Arsenic trioxide decreases AKT protein in a caspase-dependent manner
    Koren Kathleen Mann, Myrian Colombo, Wilson H. Miller · 2008 · Molecular Cancer Therapeutics
91. Nutrigenomic approaches for benefit-risk analysis of foods and food components: defining markers of health
    Ruan M. Elliott, Catalina Picó, Yvonne E.M. Dommels, Iwona Wybrańska, John E. Hesketh, Jaap Keijer · 2007 · British Journal Of Nutrition
92. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status
    Nagata · 2010 · International Journal of Oncology
93. Akt inhibitors: mechanism of action and implications for anticancer therapeutics
    Jaikrit Bhutani, Asfandyar Sheikh, Asfandyar Khan Niazi · 2013 · Infectious Agents and Cancer
94. Synergistic Allosteric Mechanism of Fructose-1,6-bisphosphate and Serine for Pyruvate Kinase M2 via Dynamics Fluctuation Network Analysis
    Jingxu Yang, Hao Liu, Xiaorui Liu, Chengbo Gu, Ray Luo, Haifeng Chen · 2016 · Journal of Chemical Information and Modeling
95. Th-POK regulates mammary gland lactation through mTOR-SREBP pathway
    Rui Zhang, Huimin Ma, Yuan Gao, Yanjun Wu, Yuemei Qiao, Ajun Geng, Cheguo Cai, Yingying Han, Yi Arial Zeng, Xiaolong Liu et al. · 2018 · PLoS Genetics
96. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction
    Marco Colombi, Klaus D. Molle, Don Benjamin, Karin F. Rattenbacher-Kiser, Christiane Schaefer, Charles Betz, Anke Thiemeyer, Urs Regenass, Michael N. Hall, Christoph Moroni · 2010 · Oncogene
97. GADD34 inhibits mammalian target of rapamycin signaling via tuberous sclerosis complex and controls cell survival under bioenergetic stress
    Ryosuke Watanabe, Yukihiro Tambe, Hirokazu Inoue, Takahiro Isono, Masataka Haneda, Ken‐ichi Isobe, Toshiyuki Kobayashi, Okio Hino, Hidetoshi Okabe, Tokuhiro Chano · 2007 · International Journal of Molecular Medicine
98. Hypoxia-inducible factors and cancer
    María José Calzada, Luis del Peso · 2007 · Clinical & Translational Oncology
99. Hedgehog inhibitor decreases chemosensitivity to 5‐fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer
    Hideya Onishi, Yoshihiro Morifuji, Masaya Kai, Kumi Suyama, Hironori Iwasaki, Mitsuo Katano · 2012 · Cancer Science
100. Modeling prostate cancer: a perspective on transgenic mouse models
     Varinder Jeet, Pamela Joan Russell, Aparajita Khatri · 2010 · Cancer and Metastasis Reviews